Modulation of protective immunity, eosinophilia, and cytokine responses by selective mutagenesis of a recombinant G protein vaccine against respiratory syncytial virus

Journal of Virology

Volumn 79, Issue 7, 2005, Pages 4527-4532

  Huang, Yan ^a   Anderson, Robert ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; PLASMID VECTOR; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; THIOREDOXIN; THIOREDOXIN G128 229; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; EOSINOPHILIA; GENE MUTATION; IMMUNITY; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SITE DIRECTED MUTAGENESIS; VACCINE PRODUCTION; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, VIRAL; CYTOKINES; EOSINOPHILIA; LUNG; MICE; MUTAGENESIS, SITE-DIRECTED; MUTATION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; RNA, MESSENGER; VACCINES, SYNTHETIC; VIRAL PROTEINS;

EID: 15244342666     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.7.4527-4532.2005     Document Type: Article

References (38)

1. Beasley, R., E. D. Coleman, Y. Hermon, P. E. Holst, T. V. O'Donnell, and M. Tobias. 1988. Viral respiratory tract infection and exacerbation of asthma in adult patients. Thorax 43:679-683.
2. Chin, J., R. L. Magoffin, L. A. Shearer, J. H. Schieble, and E. H. Lennette. 1969. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 89:449-463.
3. Connors, M., N. A. Giese, A. B. Kulkarni, C. Y. Firestone, H. C. Morse, and B. R. Murphy. 1994. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 68:5321-5325.
4. de Waal, L., S. Yuksel, A. H. Brandenburg, J. P. M. Langedijk, K. Sintnicolaas, G. M. G. M. Verjans, A. D. M. E. Osterhaus, and R. L. de Swart. 2004. Identification of a common HLA-DP4-restricted T-cell epitope in the conserved region of the respiratory syncytial virus G protein. J. Virol. 78: 1775-1781.
5. Doherty, P. C. 1994. Vaccines and cytokine-mediated pathology in RSV infection. Trends Microbiol. 2:148-149.
6. Fulginiti, V. A., J. J. Eller, O. F. Sieber, J. W. Joyner, M. Minamitani, and G. Meiklejohn. 1969. Respiratory virus immunization. I. A field trial of two inactivated virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89:435-448.
7. Glezen, W. P., L. H. Taber, A. L. Frank, and J. A. Kasel. 1986. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140:543-546.
8. Graham, B. S., G. S. Henderson, Y.-W. Tang, X. Lu, K. M. Neuzil, and D. G. Colley. 1993. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol. 151:2032-2040.
9. Graham, B. S., J. A. Rutigliano, and T. R. Johnson. 2002. Respiratory syncytial virus immunobiology and pathogenesis. Virology 297:1-7.
10. Grunig, G., M. Warnock, A. E. Wakil, R. Venkayya, F. Brombacher, D. M. Rennick, D. Sheppard, M. Mohrs, D. D. Donaldson, R. M. Locksley, and D. B. Corry. 1998. Requirement for IL-13 independently of 1L-4 in experimental asthma. Science 282:2261-2263.
11. Hancock, G. E., D. J. Hahn, D. J. Speelman, S. W. Hildreth, S. Pillai, and K. McQueen. 1994. The pulmonary immune response of BALB/c mice vaccinated with the fusion protein of respiratory syncytial virus. Vaccine 12:267-274.
12. Hancock, G. E., D. J. Speelman, K. Heers, E. Bortell, J. Smith, and C. Cosco. 1996. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J. Virol. 70:7783-7791.
13. Haynes, L. M., L. P. Jones, A. Barskey, L. J. Andersen, and R. A. Tripp. 2003. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J. Virol. 77:9831-9844.
14. Holberg, C. J., A. L. Wright, F. D. Martinez, C. G. Ray, L. M. Taussig, and M. D. Lebowitz. 1991. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am. J. Epidemiol. 133: 1135-1151.
15. Huang, Y., and R. Anderson. 2002. Enhanced immune protection by a liposome-encapsulated recombinant respiratory syncytial virus (RSV) vaccine using immunogenic lipids from Deinococcus radiodurans. Vaccine 20: 1586-1592.
16. Huang, Y., and R. Anderson. 2003. A single amino acid substitution in a recombinant G protein vaccine drastically curtails protective immunity against respiratory syncytial virus (RSV). Vaccine 21:2500-2505.
17. Hussell, T., and P. J. M. Openshaw. 1998. Intracellular IFN-γ expression in natural killer cells precedes lung CD8 T cell recruitment during respiratory syncytial virus infection. J. Gen. Virol. 79:2593-2601.
18. Johnson, T. R., and B. S. Graham. 1999. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13 and eosinophilia by an IL-4-independent mechanism. J. Virol. 73:8485-8495.
19. Johnson, T. R., R. A. Parker, J. E. Johnson, and B. S. Graham. 2003. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J. Immunol. 170:2037-2045.
20. Johnson, T. R., M. N. Teng, P. L. Collins, and B. S. Graham. 2004. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J. Virol. 78:6024-6032.
21. Kapikian, A. Z., R. H. Mitchell, R. M. Chanock, R. A. Shvedoff, and C. E. Stewart. 1969. An epidemiological study of altered clinical reactivity for respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89:405-421.
22. Kim, H, W., J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock, K. Jensen, and R. H. Parrott. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:422-433.
23. Mader, D., Y. Huang, C. Wang, R. Fraser, A. C. Issekutz, A. W. Stadnyk, and R. Anderson. 2000. Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challenge. Vaccine 18:1110-1117.
24. Neuzil, K. M., J. E. Johnson, Y. W. Tang, J. P. Prieels, M. Slaoui, N. Gar, and B. S. Graham. 1997. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine 15:525-532.
25. Openshaw, P. J. M., F. J. Culley, and W. Olszewska. 2002. Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 20:S27-S31.
26. Openshaw, P. J., S. L. Clarke, and F. M. Record. 1992. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int. Immunol. 4:493-500.
27. Plotnicky-Gilquin, H., T. Huss, J. P. Aubry, J. F. Haeuw, A. Beck, J. Y. Bonnefoy, T. N. Nguyen, and U. F. Power. 1999. Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment. Virology 258:128-140.
28. Polack, F. P., M. N. Teng, P. L. Collins, G. A. Prince, M. Exner, H. Regele, D. D. Lirman, R. Rabold, S. J. Hoffman, C. L. Karp, S. R. Kleeberger, M. Wills-Karp, and R. A. Karron. 2002. A role for immune complexes in enhanced respiratory syncytial virus disease. J. Exp. Med. 196:859-865.
29. Power, U. F., T. Huss, V. Michaud, H. Plotnicky-Gilquin, J. Y. Bonnefoy, and T. N. Nguyen. 2001. Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice. J. Virol. 75:12421-12430.
30. Ryan, E. J., L. M. Daly, and K. H. Mills. 2001. Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol. 19: 293-304.
31. Sparer, T. E., S. Matthews, T. Hussell, A. J. Rae, B. Garcia-Barreno, J. A. Melero, and P. J. Openshaw. 1998. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J. Exp. Med. 187:1921-1926.
32. Spender, L. C., T. Hussell, and P. J. M. Openshaw. 1998. Abundant IFN-γ production by local T cells in respiratory syncytial virus-induced eosinophilic lung disease. J. Gen. Virol. 79:1751-1758.
33. Srikiatkhachorn, A., and T. J. Braciale. 1997. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. J. Virol. 71: 678-685.
34. Srikiatchachorn, A., W. Chang, and T. J. Braciale. 1999. Induction of Th1 and Th2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent. J. Virol. 73: 6590-6597.
35. Tebbey, P. W., M. Hagen, and G. E. Hancock. 1998. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J. Exp. Med. 188:1967-1972.
36. Trinchieri, G. 1989. Biology of natural killer cells. Adv. Immunol. 47:187-376.
37. Varga, S. M., E. L. Wissinger, and T. J. Braciale. 2000. The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses. J. Immunol. 165:6487-6495.
38. Waris, M. E., C. Tsou, D. D. Erdman, S. R. Zaki, and L. J. Anderson. 1996. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70:2852-2860.